Company intelligence / Profile preview

Conceptra Biosciences

Ownership: Private
Development stage: Phase 3

Overview

Conceptra Biosciences has an active Phase 3 clinical trial evaluating the efficacy and safety of a CCT–102 regimen versus expectant management in first trimester delayed pregnancy loss. They are also conducting a candidate comparison study of their Clara™ Multi-Level Urine hCG Pregnancy Test. No published results yet.

Therapeutic areas: Women's Health
Modalities: Diagnostic devices (e.g., urine hCG pregnancy test)Small molecules or drug regimens (CCT-102 regimen for uterine evacuation)
Industry: Biotech

Drug pipeline

1 asset

CCT-102

Unknown

Beyond the preview

Go deeper on Conceptra Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conceptra Biosciences.

Explore the full profile